Pharmacokinetic Interactions and Safety Study of Telmisartan and Chlorthalidone

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-11-30

Study Completion Date

2013-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Clinical trial to evaluate the pharmacokinetic interactions and safety between telmisartan and chlorthalidone.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Drug-drug Interaction Study (Telmisartan, Amlodipine, Chlorthalidone)

NCT02152969

Hypertension

COMPLETED PHASE1

Study to Evaluate the Efficacy and Safety of TEL/AML/CTD in Elderly Patients with Essential Hypertension

NCT06041529

Essential Hypertension

RECRUITING PHASE4

Efficacy and Safety of TAH Combination in Comparison With Telmisartan/Amlodipine Combination for Essential Hypertension Patients

NCT02738632

Essential Hypertension

COMPLETED PHASE3

S-amlodipine+Chlorthalidone vs S-amlodipine+Telmisartan in Hypertension

NCT03226340

Essential Hypertension

UNKNOWN PHASE4

Clinical Trial to Compare the Safety and Pharmacokinetics of YH22162 in Healthy Volunteers

NCT03662620

Hypertension

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Part A: Telmisartan, Chlorthalidone + Telmisartan

telmisartan 80mg : multiple dose administered orally chlorthalidone 25mg : multiple dose administered orally

Group Type ACTIVE_COMPARATOR

Telmisartan 80mg

Intervention Type DRUG

Chlorthalidone 25mg

Intervention Type DRUG

Part B: Chlorthalidone, Chlorthalidone + Telmisartan

telmisartan 80mg : multiple dose administered orally chlorthalidone 25mg : multiple dose administered orally

Group Type ACTIVE_COMPARATOR

Telmisartan 80mg

Intervention Type DRUG

Chlorthalidone 25mg

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Telmisartan 80mg

Intervention Type DRUG

Chlorthalidone 25mg

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Healthy male subjects
2. Age(yr)between 20 and 50
3. Signed written informed consent

Exclusion Criteria

1. Known hypersensitivity to investigator product, thiazide, sulphonamide and other drugs or additive.
2. History of any siginificant Sickness, Cardiovascular, Respiratory, Renal, Endocrine, Neurological, Psychic, Cancer, Gasstrointestinal, Hematologic.
3. History of drug and/or alcohol abuse
4. Over 10 tobaccos a day
5. Other condition which in the opinion of the investigator preclude enrollment into the study

Minimum Eligible Age

20 Years

Maximum Eligible Age

50 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes